Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences is a commercial-stage biopharmaceutical company with a positive outlook, as they have a strong pipeline of drug candidates, including VTAMA, Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. Their recent clinical data for brepocitinib in cutaneous sarcoidosis and dermatomyositis has demonstrated potential for rapid and profound improvement and a significant market opportunity in these rare diseases. With a robust dataset and multiple catalysts on the horizon, the company is well-positioned for potential commercial success.

Bears say

Roivant Sciences is facing significant challenges in its drug development pipeline, as it has multiple drugs in various stages of development but lacks a track record of successful commercialization. In addition, the company's current financials are not strong, with low revenue and high non-GAAP loss per share. There is also a lack of clarity on the development plans for other assets, which could pose a risk to achieving the projected revenue estimate for 2036. Furthermore, Roivant may face tough competition in the commercial space from larger and more experienced players.

ROIV has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 9 analysts, ROIV has a Buy consensus rating as of May 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.